Variable results after rituximab in neuromyelitis optica
Variable results after rituximab in neuromyelitis optica
复制标题
DOI：
10.1016/j.jns.2012.02.017
复制
发表时间：
2012-06-15
影响因子：
4.4
通讯作者：
Wolinsky, J. S.
中科院分区：
文献类型：
--
作者：
Lindsey, J. W.;Meulmester, K. M.;Wolinsky, J. S.
我们的目的是评估利妥昔单抗（RTX）在视神经肌萎缩症（NMO）中的疗效。我们对作者亲自治疗的病例进行了回顾性分析。我们确定了9名符合NMO或复发性纵向广泛横肌萎缩（LETM）标准的受试者，他们接受了RTX治疗，并记录了他们的临床病程。9名受试者中有6名在RTX治疗后继续复发。RTX是五名受试者在诊断后使用的第一种免疫抑制治疗，其中四名继续复发。我们的结论是，在NMO的RTX治疗后的结果是不一致的。观察到的变异性可能反映了个体之间疾病活动的差异、疾病活动随时间的差异或NMO潜在免疫发病机制的差异。需要更有效的治疗。(C)2012爱思唯尔有限公司版权所有。
Our objective was to assess the efficacy of rituximab (RTX) in neuromyelitis optica (NMO). We conducted a retrospective review of cases personally treated by the authors. We identified nine subjects meeting criteria for either NMO or recurrent longitudinally extensive transverse myelitis (LETM) who were treated with RTX and documented their clinical course. Six of the nine subjects continued to have relapses after RTX treatment. RTX was the first immunosuppressive treatment used after diagnosis in five subjects, and four of these continued to have relapses. We conclude that outcomes after RTX treatment of NMO are inconsistent. The observed variability may reflect differences in disease activity between individuals, differences in disease activity over time, or differences in the underlying immunopathogenesis of NMO. More effective treatments are needed. (C) 2012 Elsevier B.V. All rights reserved.